S

SELLAS Life Sciences Group

D
SLS
USD
-0.015
(-1.2146%)
Market Closed
3,799.00
Volume
-0.59
EPS
-
Div Yield
-1.355556
P/E
78,485,647.56
Market Cap
Today
-1.2146%
1 Week
-7.576%
1 Month
-12.230%
6 Months
15.094%
12 Months
-18.667%
Year To Date
16.190%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
APEN
0.02
(0.2023%)
USD
A
ADMP
(%)
USD
A
AXSM
2.77
(3.0257%)
USD
A
AQST
0.255
(5.1567%)
USD
C
CNCE
(%)
USD
E
EOLS
0.24
(1.4806%)
USD
E
EGRX
-0.04
(-0.9195%)
USD
E
EVOK
-0.01
(-0.2278%)
USD
I
INSM
2.06
(2.8266%)
USD
I
ICPT
(%)
USD

Title:
SELLAS Life Sciences Group

Sector:
Healthcare
Industry:
Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Do you need help or have a question?
Contact Us